Anti-bovine leukemia virus gp51 protein monoclonal antibody with competitive activity as well as preparation method and application thereof
By expressing and purifying the eukaryotic recombinant protein of bovine leukemia virus in insect cells, monoclonal antibodies were prepared, and the existing BLV detection methods rely on foreign reagents and lack of domestic kits were solved, achieving efficient and economical detection of gp51 antibody , promotes the diagnosis and monitoring of BLV.
Patent Information
- Application Number
- CN202410908628.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-08
- Publication Date
- 2024-11-22
AI Technical Summary
The existing BLV detection methods for bovine leukemia virus rely on imported reagents from abroad and lack domestic commercial kits. In particular, there is insufficient detection of gp51 antibodies, resulting in high detection costs and difficulty in monitoring BLV infection.
By expressing the eukaryotic recombinant protein of bovine leukemia virus gp51 in insect cells and preparing monoclonal antibodies against the eukaryotic recombinant protein of bovine leukemia virus gp51, cell fusion technology was used to obtain stable secreted hybridoma cell 3E3 for competition for ELISA assay Detect gp51 antibody.
A simple and reliable method is provided to detect BLV gp51 antibodies, which reduces detection costs, improves detection efficiency, and solves the shortcomings of gp51 antibody detection in the prior art, and promotes the diagnosis and monitoring of BLV.
Smart Images

Figure CN118994330A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of bovine biological products and diagnostic reagents, and specifically relates to a monoclonal antibody with competitive activity against bovine leukemia virus gp51 protein, and a preparation method and application thereof. Background Art
[0002] Bovine leukemia virus (BLV) is the pathogen of enzootic bovine leukosis (EBL). After infection, it can cause B-cell lymphosarcoma, which is prevalent to varying degrees in most parts of the world. The incubation period of EBL is relatively long, generally 3-8 years, so BLV infection is easily underestimated and ignored. A large amount of data shows that infection with BLV can cause immune disorders to a certain extent, leading to increased incidence of other infectious diseases, as well as reduced milk production and reproductive efficiency, resulting in large economic losses. Clinical symptoms after infection with BLV include reduced milk production, superficial lymphadenopathy, digestive disorders, loss of appetite, lameness, paralysis, etc. At the same time, the nausea and vomiting lymphoma caused by BLV can invade multiple organs such as the uterus, spleen, lungs, and kidneys, leading to urinary, respiratory and digestive system diseases. The economic losses caused by BLV infection are not only caused by reduced milk production, but also because some countries and regions have implemented strict import and export controls on animals infected with BLV, which will indirectly cause economic losses. There is currently no effective treatment or vaccine for BLV infection. The main prevention and control measure is to kill or isolate infected cattle. Therefore, the detection of BLV plays an important role in the prevention, control and monitoring of the disease.
[0003] BLV belongs to the family of Retroviridae. Its genetic material is single-stranded RNA. Its virus particles are spherical, have a double-layer membrane structure, and its nucleocapsid is icosahedral symmetric. The structural genes of BLV are divided into gag, pol, pro, and env, which are mainly responsible for the infection and replication of the virus. These four structural genes are responsible for encoding different proteins, among which the gag gene is responsible for encoding the matrix protein p15, the capsid protein p24, and the nucleocapsid protein p12; the env gene is responsible for encoding the extracellular protein gp51 and the transmembrane protein gp30. Currently, the commonly used diagnostic methods include serological antibody detection and proviral DNA detection. Among them, the serological detection method is mainly based on the two targets of capsid protein p24 (the main target in the host immune response) and cell membrane protein gp51 (which can induce infected animals to produce a large amount of antibodies). Reports show that during the artificial infection of BLV, gp51 antibodies appear earlier and have higher titers than p24 antibodies. At present, almost all the bovine leukemia serological detection reagents used in my country are from abroad, which are expensive, resulting in increased detection costs. However, there is currently a lack of commercial test kits in China for detecting gp51 antibodies after BLV infection. Summary of the invention
[0004] The purpose of this section is to summarize some aspects of embodiments of the present invention and briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section and the specification abstract and the invention title of this application to avoid blurring the purpose of this section, the specification abstract and the invention title, and such simplifications or omissions cannot be used to limit the scope of the present invention.
[0005] In view of the above problems and / or the problems existing in the prior art, the present invention is proposed.
[0006] Therefore, the purpose of the present invention is to overcome the deficiencies in the prior art and provide a bovine leukemia virus gp51 eukaryotic recombinant protein.
[0007] To solve the above technical problems, the present invention provides the following technical solution: the bovine leukemia virus gp51 eukaryotic recombinant protein is expressed in insect cells sf9, and its nucleic acid sequence is shown in SEQ ID NO.1, and its amino acid sequence is shown in SEQ ID NO.2.
[0008] Another object of the present invention is to overcome the deficiencies in the prior art and provide a monoclonal antibody against the eukaryotic recombinant protein of bovine leukemia virus gp51.
[0009] The monoclonal antibody against the eukaryotic recombinant protein of bovine leukemia virus gp51 is obtained by immunizing with the eukaryotic recombinant protein of bovine leukemia virus gp51 as an antigen.
[0010] Another object of the present invention is to overcome the deficiencies in the prior art and provide a recombinant plasmid, characterized in that: after the recombinant plasmid is transfected into mammalian cells, it expresses a gene containing the bovine leukemia virus gp51 eukaryotic recombinant protein, and its nucleotide sequence is shown in SEQ ID NO.3.
[0011] Another object of the present invention is to overcome the deficiencies in the prior art and provide a receptor cell, characterized in that the receptor cell is a transfected cell of the recombinant plasmid described in claim 3.
[0012] Another object of the present invention is to overcome the deficiencies in the prior art and provide a method for preparing monoclonal antibodies against the bovine leukemia virus gp51 eukaryotic recombinant protein.
[0013] As a preferred embodiment of the preparation method of the present invention, the bovine leukemia virus gp51 sequence is codon-optimized in an insect cell expression system and then constructed into a pFastBac-HTA eukaryotic expression donor plasmid, which is then transposed into DH10Bac competent cells to obtain the corresponding shuttle bacmid;
[0014] The shuttle bacmid was transfected into Sf9 insect cells to obtain recombinant baculovirus;
[0015] Lyse Sf9 cells infected with rBv-gp51 to obtain eukaryotically expressed recombinant gp51 protein, and purify the baculovirus-expressed recombinant protein using a Ni column;
[0016] BALB / c mice were immunized three times with purified recombinant gp51 protein combined with Freund's adjuvant, and the spleen was fused with SP2 / 0 cells and positive hybridoma cells were screened by indirect ELISA.
[0017] Another object of the present invention is to overcome the deficiencies in the prior art and provide a hybridoma cell 3E3 that stably secretes a monoclonal antibody against the eukaryotic recombinant protein of bovine leukemia virus gp51, characterized in that: the hybridoma cell 3E3 has a deposit number of CCTCC NO: C2024192, a deposit date of July 2, 2024, and a deposit unit of the China Center for Type Culture Collection, and a deposit unit address of the China Center for Type Culture Collection, Wuhan University, Wuhan, China. It reacts with eukaryotically expressed recombinant gp51 protein and native conformation / denatured gp51 protein, and the antibody subtype is IgM.
[0018] Another object of the present invention is to overcome the deficiencies in the prior art and provide a use of hybridoma cell 3E3 in the competitive ELISA test for detecting bovine leukemia virus gp51 antibodies.
[0019] As a preferred embodiment of the application of the present invention, in the competitive ELISA test for detecting bovine leukemia virus gp51 antibodies, the bovine leukemia virus gp51 eukaryotic recombinant protein is used as the coating antigen and the hybridoma cell 3E3 culture supernatant is used as the competing antibody to carry out a blocking ELISA experiment.
[0020] As a preferred embodiment of the application of the present invention, the competitive ELISA test for detecting bovine leukemia virus gp51 antibody is as follows: 0.125 μg / mL of recombinant gp51 eukaryotic expression protein is coated in an enzyme-labeled plate, 100 μL / well, and coated overnight at 4°C; the plate is washed with PBST; 200 μL of 1% BSA per well is blocked at 37°C for 2 hours; the plate is washed with PBST; 50 μL of 5-fold diluted serum sample is added and incubated at 37°C for 1 hour; 50 μL of competitive antibody 3E3 hybridoma culture supernatant is added and incubated at 37°C for 1 hour, and the plate is washed with PBST; 50 μL of diluted Goat Anti-Mouse IgM HRP is added to each well and incubated at 37°C for 30 minutes; PBST is washed; 100 μL of TMB colorimetric solution is added and color is developed at room temperature in the dark for 10 minutes; 50 μL of colorimetric stop solution is used to stop color development; and reading is performed using an enzyme marker.
[0021] As a preferred embodiment of the preparation method of the present invention, after the reading, the S / N value is calculated according to the OD value, and the detection result S / N value ≤ 0.4915 is judged as positive; S / N value ≥ 0.6534 is judged as negative, and 0.4915<S / N value<0.6534 is judged as suspected.
[0022] Beneficial effects of the present invention:
[0023] The present invention uses a baculovirus expression system to prepare a eukaryotic recombinant gp51 protein, and the recombinant gp51 protein expressed by the system can be correctly folded and post-translationally modified, and has biological activity. The eukaryotic recombinant gp51 protein is used as an immunogen to immunize mice, and a monoclonal antibody against the gp51 protein is prepared by cell fusion technology. The prepared monoclonal antibody can be used to establish a blocking ELISA for detecting gp51 antibodies, providing a simple and reliable verification method for the diagnosis of BLV. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the following briefly introduces the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative labor. Among them:
[0025] Figure 1 The pFastBac-HTA-gp51 plasmid of Example 1 of the present invention is constructed, wherein Figure 1 (a) is gp51 gene amplification, Figure 1 (b) Linearization of recombinant bacmid virus vector, Figure 1 (c) is a plasmid map.
[0026] Figure 2 For the IFA identification of the eukaryotic expression of BLV gp51 in Example 2 of the present invention, Figure 2 (a) is Sf9 cells infected with rBv-gp51, Figure 2 (b) is a picture of blank Sf9 cells.
[0027] Figure 3 The expression, purification and identification of BLV gp51 in Example 2 of the present invention, wherein: Figure 3 (a) for eukaryotic expression, Figure 3 (b) is protein purification, Figure 3 (c) Western Blot identification.
[0028] Figure 4 is the identification diagram in Embodiment 4 of the present invention, wherein: Figure 4 (a) is the recognition of eukaryotic recombinant protein by monoclonal antibody, Figure 4(b) Recognition of denatured native protein.
[0029] Figure 5 The IFA method for identifying the recognition activity of the monoclonal antibody against the natural chIFN-γ protein in Example 5 of the present invention is as follows: Figure 5 (a) is mouse polyclonal antiserum, Figure 5 (b) is gp51-2A11, Figure 5 (c) is gp51-3E3, Figure 5 (d) is the gp51-4E12 map.
[0030] Figure 6 This is a diagram for determining the relevant conditions in the BLV gp51 antibody blocking ELISA detection method in Example 6 of the present invention, wherein: Figure 6 (a) Determination of the optimal coating conditions, Figure 6 (b) Determination of the optimal blocking solution Figure 6 , (c) Determination of the optimal sample dilution, Figure 6 (d) Determination of the optimal antibody reaction time, Figure 6 (e) Determination of enzyme-labeled antibody incubation time, Figure 6 (f) Determination of color development time.
[0031] Figure 7 This is to determine the positive and negative judgment criteria of the BLV gp51 antibody blocking ELISA detection method in Example 6 of the present invention.
[0032] Figure 8 This is the specificity of the blocking ELISA antibody detection method in Example 6 of the present invention. DETAILED DESCRIPTION
[0033] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific implementation methods of the present invention are described in detail below in conjunction with the embodiments of the specification.
[0034] In the following description, many specific details are set forth to facilitate a full understanding of the present invention, but the present invention may also be implemented in other ways different from those described herein, and those skilled in the art may make similar generalizations without violating the connotation of the present invention. Therefore, the present invention is not limited to the specific embodiments disclosed below.
[0035] Secondly, the term "one embodiment" or "embodiment" as used herein refers to a specific feature, structure, or characteristic that may be included in at least one implementation of the present invention. The term "in one embodiment" that appears in different places in this specification does not necessarily refer to the same embodiment, nor does it refer to a separate or selective embodiment that is mutually exclusive with other embodiments.
[0036] The raw materials used in the examples of the present invention are commercially available unless otherwise specified, as shown in Table 1.
[0037] Among them, the culture name (classification and naming): Hybridoma cellline 3E3; preservation number: CCTCC NO:C2024192, preservation date: 2024.7.2.
[0038] Table 1
[0039]
[0040] Example 1
[0041] Construction of recombinant baculovirus rBv-gp51:
[0042] The gp51 gene sequence published by NCBI (https: / / www.ncbi.nlm.nih.gov / ) was compared, and the base combination with the highest frequency in the variant site was selected to determine the sequence as gp51 LC007988.1. The insect cell expression system codon was optimized, and amplification primers were designed and inserted into EcoRⅠ and HindⅢ restriction sites. The gene was synthesized by GenScript Biotech Co., Ltd.
[0043] A pair of specific primers was designed based on the synthesized BLV gp51 gene sequence (Table 2), and the homology arm sequence of the vector plasmid pFastBac-HTA (in bold font) was added to the 5' end of the upstream and downstream primers. At the same time, two pairs of homology primers for vector linearization were designed by analyzing the vector pFastBac-HTA sequence. The amplification size was 4856 bp, and the homology sequence of the BLV gp51 gene (underlined) was added to the 5' end of the upstream and downstream primers.
[0044] Table 2
[0045] Primers 5'→3' F-gp51 <![CDATA[ AAGGCCTACGTCGACGAGAA TTCATGCCTAAGGAGCGGAGAA]]> R-gp51 <![CDATA[ GGCCGCACTAGTTGAGC AAGCTTTCAACTCCGACGAACCCGG]]> F-pF-gp51 CGGAGTTGAAAGCTTGCTCAACTAGTGCGGCC R-pF-gp51 CTTAGGCATGAATTCTCGTCGACGTAGGCCTT F-M13 TGTAAAACGACGGCCAGT R-M13 CAGGAAACAGCTATGACC
[0046] The gp51 target gene and the linearized pFastBac-HTA vector were amplified using specific primers with the synthetic gp51 gene and pFastBac-HTA plasmid as templates. Figure 1 As shown, the band sizes were 916bp and 4856bp, respectively, which was consistent with expectations. The pFastBac-HTA linearized fragment was connected to the gp51 fragment by homologous recombination, and the connected recombinant baculovirus vector was named pFastBacHTA-BLV-gp51. The constructed plasmid was identified using primer gp51. The results showed that the gp51 target gene with a size of 916bp was successfully inserted into the linearized vector pFastBac-HTA by homologous recombination. The sequencing results showed that no mutations or deletions were found in the sequence.
[0047] The constructed recombinant baculovirus vector pFastBacHTA-BLV-gp51 was transposed into the DH10Bac competent medium, and the recombinant shuttle bacmid was subsequently obtained by blue-white screening and named rB-gp51. In order to verify the construction of the recombinant baculovirus shuttle plasmid, the universal primer M13 (primer sequence see Table 2) was used to identify the extracted bacmid. The amplified band size was 4777bp and the sequencing results showed no deletion or mutation in the sequence, and the correct recombinant baculovirus shuttle bacmid was successfully obtained. Figure 1 The pFastBac-HTA-gp51 plasmid of Example 1 of the present invention is constructed, wherein Figure 1 (a) is gp51 gene amplification, Figure 1 (b) Linearization of recombinant bacmid virus vector, Figure 1 (c) is a plasmid map.
[0048] Example 2
[0049] Expression and purification of recombinant gp51 protein:
[0050] The constructed rB-gp51 recombinant shuttle bacmid was transfected into Sf9 cells using LipofectamineTM3000. After 7 days of transfection, the cell infection was observed, the cells and their supernatant were collected, and centrifuged at 10000r / min for 10min at 4°C. The supernatant was collected, which was the P1 generation virus rBv-gp51 and stored at -80°C. At the same time, rB-pFastBac-HTA was transfected as a negative control. After 5 days of infection of Sf9 cells with the P1 generation virus, the cells and their supernatant were collected and centrifuged as above to obtain the P2 generation virus. Similarly, the P3 generation virus was prepared as the recombinant baculovirus used later.
[0051] Four days after the P3 generation rBv-gp51 virus was infected into Sf9 cells, IFA was performed. Anti-His-tag antibody was used as the primary antibody and FITC-GoatAnti-Mouse IgG was used as the secondary antibody. The results are shown in Figure 2. Figure 2 As shown, Figure 2 a: Sf9 cells infected with rBv-gp51 have specific green fluorescence. Figure 2 b: Sf9 cells infected with rBv-pFastBac-HTA showed no fluorescence. The P3 generation of rBv-gp51 was used to infect cultured Sf9 cells. Cell pellets were harvested 4 days after infection and subjected to SDS-PAGE after being disrupted. The size of the harvested protein was about 43 kDa. Figure 3 To further prove the expression of recombinant gp51 protein, WB test was performed using anti-His-tag monoclonal antibody and GoatAnti-Mouse IgG HRP secondary antibody. Figure 3As shown, a specific band can be detected at about 43 kDa in the supernatant of Sf9 cell lysis infected by rBv-gp51, which is consistent with the expected size of recombinant gp51 protein; while no specific band was detected in the supernatant of blank Sf9 cell lysis. The results show that Sf9 cells infected with rBv-gp51 can recombinantly express gp51 protein and it is mainly expressed in cells.
[0052] The P3 virus was inoculated into Sf9 cells cultured in T25 cell flasks, and the cells were collected after culturing in a 27°C constant temperature incubator for 4 days. The collected cells were broken and protein was purified using the His tag protein purification kit of Biyuntian. The washing solution (W2, W3) and the elution solution (E1, E2) were analyzed by SDS-PAGE. The results are shown in Figure 3 As shown, the purified recombinant gp51 protein was obtained at about 43 kDa. The protein was quantified by the BSA method, and the concentration of the purified recombinant gp51 protein was 0.5 mg / mL.
[0053] Example 3
[0054] Preparation of mouse monoclonal antibody against BLV gp51 protein:
[0055] The main steps of monoclonal antibody preparation are: mouse immunization, cell fusion, hybridoma cell screening, cell monoclonal cloning, antibody identification, and ascites preparation.
[0056] Purified recombinant gp51 protein was used as an immunogen combined with Freund's adjuvant to immunize 6-week-old female BALB / c mice. The specific immunization procedure was three intraperitoneal injections of 40 μg of recombinant gp51 protein and Freund's adjuvant emulsion, each with an interval of 2 weeks; one intraperitoneal injection of 40 μg of recombinant gp51 protein for shock immunization. On the 7th day after the third immunization, tail vein blood was collected to detect the titer. Three days after the shock immunization, mouse spleen cells were taken and fused with SP2 / 0 cells under the action of 50% PEG-1500, and added to the feeder layer cells containing HAT culture medium, and placed in a 37°C, 5% CO2 cell culture incubator. Half of the medium was changed after 5 days, and after 10 days, it was changed to DMEM complete culture medium containing HT. The culture supernatant of hybridoma cells coated with recombinant gp51 protein was determined by indirect ELISA method, and the positive wells were subcloned by limiting dilution method. The positive hybridoma wells were subcloned 2 to 3 times in succession, and finally expanded and cultured, and frozen. The monoclonal antibody hybridoma cell culture supernatant was collected, and the antibody typing kit of Bio-Long was used to identify the antibody type and subtype of the obtained monoclonal antibodies (2A11, 3E3, 4E12). The subtype identification test results showed that the monoclonal antibodies 2A11, 3E3, and 4E12 against gp51 protein were all IgM type.
[0057] BALB / c mice aged about 10 weeks were selected and intraperitoneally inoculated with 0.5 mL of pristane. After 7 to 10 days, monoclonal hybridoma cells diluted with PBS were intraperitoneally inoculated with 5 × 10 cells. 5 After 7 days, the abdominal distension was observed, ascites was collected, the precipitate was removed by centrifugation, the supernatant was collected, the titer was measured, and the cells were stored at -80°C.
[0058] Example 4
[0059] Western blot assay to identify the monoclonal antibody's recognition activity against eukaryotic expressed chIFN-γ protein and natural chIFN-γ protein:
[0060] Purified recombinant gp51 protein was used as a sample for WB test, the primary antibody was 2A11, 3E3, 4E12 hybridoma culture supernatant, GoatAnti-Mouse IgM HRP was used as a secondary antibody, and the luminescent colorimetric solution was used for development. Figure 4 As shown, the obtained 2A11, 3E3, and 4E12 monoclonal antibodies can specifically recognize the recombinant gp51 protein expressed by the baculovirus expression system, which is consistent with the expected band size.
[0061] The bat lung cells Tb 1Lu-BLV17985 (China Center for Type Culture Collection, CCTCC NO: C202276) prepared in the laboratory and stably infected with wild bovine leukemia virus were used as samples. The Tb 1Lu-BLV17985 cells were lysed to obtain protein samples for WB test. The primary antibody was the culture supernatant of 2A11, 3E3, and 4E12 hybridomas, GoatAnti-Mouse IgM HRP was used as the secondary antibody, and the luminescent colorimetric solution was used for development. The results are shown in Figure 4 As shown, the obtained 2A11 and 3E3 monoclonal antibodies can specifically recognize the recombinant gp51 protein expressed by the baculovirus expression system, which is consistent with the expected band size.
[0062] Example 5
[0063] IFA identified the recognition activity of monoclonal antibodies against natural chIFN-γ protein:
[0064] The cultured Tb 1Lu-BLV17985 cells were plated in 96-well cell culture plates in advance. After overnight culture, the membranes were fixed and broken using a 1:1 mixture of ethanol and acetone. The IFA test was performed using the culture supernatant of 2A11, 3E3, and 4E12 hybridomas as the primary antibody and FITC-GoatAnti-Mouse IgG as the secondary antibody. The results were observed under a fluorescence microscope. Figure 5As shown, mouse polyclonal antiserum and 2A11, 3E3, 4E12 monoclonal supernatants all had specific green fluorescence, while the negative control group had no green fluorescence, indicating that mouse polyclonal antiserum and 2A11, 4E12, 3E3 monoclonal cell supernatants could recognize the natural gp51 protein with spatial conformation in Tb 1Lu-BLV17985 cells.
[0065] Example 6
[0066] Establishment and optimization of BLV gp51 antibody blocking ELISA detection method:
[0067] (1) Antibody screening for BLV gp51 antibody blocking ELISA test:
[0068] Blocking ELISA tests were performed using three mAbs against gp51 protein. The steps are as follows: 1 μg / mL recombinant gp51 protein was coated on the ELISA plate, 100 μL / well, coated overnight at 4°C; washed the plate 3 times with PBST; blocked with 200 μL 1% BSA per well at 37°C for 2h; washed the plate 3 times with PBST; added 50 μL of 2-fold diluted positive and negative bovine serum samples and incubated at 37°C for 1h; added 50 μL of hybridoma culture supernatant and incubated at 37°C for 1h, washed the plate 3 times with PBST; added 50 μL of diluted GoatAnti-Mouse IgMHRP to each well, incubated at 37°C for 30min; washed with PBST; added 100 μL TMB colorimetric solution, color developed at room temperature in the dark for 10min; stopped color development with 50 μL colorimetric stop solution; read using an ELISA reader.
[0069] The blocking efficiency of the three mAbs was calculated (blocking rate = [1-(OD sample / OD negative control)] × 100%. The results are shown in Table 3. The blocking rate of 2A11 was 12.6%, the blocking rate of 3E3 was 76.5%, and the blocking rate of 4E12 was 12.7%. Among the three strains, gp51-3E3 had the best blocking effect, so 3E3 was used for the establishment of the subsequent blocking ELISA method.
[0070] Table 3
[0071] Cell lines Positive serum Negative serum Blocking rate gp51-2A11 1.419±0.086 1.625±0.030 12.6% gp51-3E3 0.538±0.009 2.293±0.022 76.5% gp51-4E12 1.777±0.086 2.036±0.037 12.7%
[0072] (2) Determination of relevant conditions in the BLV gp51 antibody blocking ELISA detection method:
[0073] The optimal antigen coating concentration and standard positive and negative serum dilution multiples for the blocking ELISA test were determined. The protein was coated at concentrations of 0.5μg / mL, 0.25μg / mL, 0.125μg / mL, 0.06μg / mL, and 0.03μg / mL using the matrix method, with 100μL per well. The primary antibody was diluted at a ratio of 1 / 2, 1 / 5, 1 / 10, and 1 / 20 for positive and negative serum. The P / N value was calculated based on the OD450 value of each positive and negative well, where P was the positive serum value and N was the negative serum value. The group with the lowest P / N value was selected as the antigen coating concentration and serum dilution multiple for subsequent experiments. The results are shown in Table 4. When the gp51 protein coating concentration was 0.125μg / mL and the positive and negative serum dilution multiple was 5 times, the P / N value was the lowest. Therefore, 0.125μg / mL was determined to be the optimal coating concentration of the gp51 antigen, and the optimal serum dilution multiple was 5 times.
[0074] Table 4
[0075]
[0076]
[0077] The ELISA plate was coated according to the optimal antigen coating concentration, and placed at 4℃ for 20h, 4℃ for 12h, and 37℃ for 3h for coating, and the test was carried out. Figure 6 As shown in the figure, it can be determined from the P / N value that the coating effect at 37°C for 3h is the best, indicating that gp51 protein is more suitable for coating at 37°C.
[0078] 2% BSA, 1% BSA, 5% skim milk, and 2.5% skim milk were used as blocking solutions, 200 μL per well, and incubated at 37°C for 2 h. The P / N value was calculated based on the OD450 absorbance value to determine the best blocking solution. Figure 6 As shown, the P / N value was the smallest when 1% BSA was used as the blocking solution.
[0079] Use PBS and PBST to dilute the test samples at a dilution ratio of 1 / 5, and determine the best sample dilution based on the P / N value. Figure 6 As shown, the P / N value is lower when PBS is used as sample diluent.
[0080] After the ELISA plate was coated at the optimal coating concentration, it was blocked and then the diluted serum sample to be tested was added, 50 μL per well, and the blocking ELISA test was performed at 37°C for 45 min, 1 h, 1.5 h and 2 h. Figure 6 As shown, the best reaction time for serum was 1 h of incubation, and the P / N value was the lowest.
[0081] After incubation with serum and monoclonal antibody for the optimal incubation time, add the diluted enzyme-labeled antibody to the ELISA plate and react at 37°C for 30 min, 45 min, and 60 min, respectively, to conduct the test. Figure 6 As shown, the optimal reaction time of enzyme-labeled antibody is 45min.
[0082] In order to find the best color development time, 100 μL of TMB color development solution was added to each well, and the reaction time was 5 min, 8 min, 10 min and 15 min respectively. After the color development was stopped with the stop solution, the best color development time was determined according to the P / N value. Figure 6 As shown, 10 min is the optimal color development time.
[0083] (3) Determination of the positive and negative criteria for the BLV gp51 antibody blocking ELISA test method:
[0084] Prepare 30 samples of sera that were negative after being tested by imported commercial ELISA kits and FRET-qPCR methods, and perform blocking ELISA tests under the above optimized optimal reaction conditions, while setting standard negative serum as a control. Calculate the S / N value of each sample based on the measured OD450 value, where S is the test sample value and N is the average value of the negative control sample. The average value is then calculated. and standard deviation (SD). is negative, For suspected For suspected samples, a second test is performed and the test results is negative, The results are as follows: Figure 7 As shown, X is 0.9772 and SD is 0.1619. The test result S / N value ≤ 0.4915 is judged as positive; S / N value ≥ 0.6534 is judged as negative, and 0.4915 < S / N value < 0.6534 is judged as suspected.
[0085] (4) Evaluation of the specificity of the BLV gp51 antibody blocking ELISA assay:
[0086] The established BLV gp51 blocking ELISA method was used to test the specificity of the detection method for positive sera of bovine reovirus (BRV), bovine viral diarrhea virus (BVDV), bovine lumpy skin disease virus (LSDV), bovine coronavirus (BCOV), bovine herpes virus type 1 (BHV-1), and Akabane virus (AKAV). At the same time, BLV positive and negative sera were set as controls, and the OD values were measured. The specificity of the method was analyzed based on the S / N values of the tested samples. The results are shown in Figure 8As shown, except for the BLV positive serum test result, the other serum test results were negative, indicating that this method has no cross reaction with other virus antibodies and has good specificity.
[0087] (5) Analysis of the compliance rate of BLV gp51 antibody blocking ELISA detection method:
[0088] In order to verify the reliability of the established blocking ELISA method, 25 sera were tested and blocked by ELISA using a foreign commercial kit. The blocking ELISA test determined the positive and negative of the serum by calculating the S / N value, and analyzed it with the results of the foreign commercial kit to calculate the coincidence rate.
[0089] Results: 7 negative sera and 18 positive sera were detected by foreign commercial kits. Among them, 7 negative sera determined by foreign commercial kits were detected by blocking ELISA method as 4 negative sera and 3 positive sera. 18 positive sera determined by foreign commercial kits were detected by blocking ELISA method as 2 negative sera and 16 positive sera. The total consistency rate between the blocking ELISA detection method and the results of foreign commercial kits was 80%.
[0090] It should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention can be modified or replaced by equivalents without departing from the spirit and scope of the technical solutions of the present invention, which should all be included in the scope of the present invention.
[0091] The nucleic acid sequence of the anti-bovine leukemia virus gp51 eukaryotic recombinant protein is shown in SEQ ID NO.1: GAATTCATGCCTAAGGAGCGGAGAAGTCGCAGACGACCCCAGCCGATTATTCGATGGGTATCACTGACATTAACACTTTTGGCCCTATGTAGGCCAATCCAGACGTGGAGGTGTTCGCTGAGCCTTGGTAACCAGCAGTGGATGACTGCTTATAATCAGGAAGCGAAATTCAGTATCTCTATCGACCAAATTTTGGAAGCCCATAACCAATCACCCTTTTGTGCCAAGTCACCTCGCTATACTCTTGACTCCGTAAACGGATATCCTAAAATTTACTGGCCCCCACCTCAAGGTAGGCGAAGGTTCGGCGCCCGCGCAATGGTTACTTACGACTGCGAACCCCGTTGTCCCTATGTGGGGGCTGATCGCTTCGACTGCCCTCACTGGGACAATGCCAGCCAAGCGGATCAGGGGTCTTTCTACGTAAATCATCAGATATTATTTCTCCACTTAAAACAATGTCATGGTATATTTACGCTAACGTGGGAGATCTGGGGCTACGATCCTCTAATAACTTTTTCGTTGCATAAGATCCCGGATCCGCCACAGCCTGACTTTCCGCAGCTCAATTCCGATTGGGTTCCCAGCGTGCGTTCTTGGGCGCTCCTACTCAACCAAACAGCAAGAGCGTTCCCCGATTGCGCAATATGCTGGGAGCCAAGCCCACCCTGGGCACCGGAGATTCTTGTCTATAATAAAACCATTTCCTCATCGGGACCAGGATTGGCATTGCCAGATGCTCAAATATTCTGGGTCAACACCTCGAGTTTTAACACAACCCAAGGCTGGCACCACCCTAGCCAGCGTCTTCTGTTCAATGTCAGTCAAGGGAATGCTCTGTTATTACCGCCAATATCTCTGGTGAACCTATCCACGGCTTCGTCTGCGCCGCCGACCCGGGTTCGTCGGAGTTGAAAGCTT
[0092] The amino acid sequence is as shown in SEQ ID NO.2:
[0093] PEFMPKERRSRRRPQPIIRWVSLTLTLLALCRPIQTWRCSLSLGNQQWMTAYN
[0094] QEAKFSISIDQILEAHNQSPFCAKSPRYTLDSVNGYPKIYWPPPQGRRRFGAR
[0095] AMVTYDCEPRCPYVGADRFDCPHWDNASQADQGSFYVNHQILFLHLKQCH
[0096] GIFTLTWEIWGYDPLITFSLHKIPDPPQPDFPQLNSDWVPSVRSWALLLNQTA
[0097] RAFPDCAICWEPSPPWAPEILVYNKTISSSGPGLALPDAQIFWVNTSSFNTTQGWHHPSQRLLFNVSQGNALLLPPISLVNLSTASSAPPTRVRRS*
[0098] The recombinant plasmid nucleic acid sequence is shown in SEQ ID NO.3:
[0099]
[0100] GCCAAGCGGATCAGGGGTCTTTCTACGTAAATCATCAGATATTATTTCTC
[0101] CACTTAAAACAATGTCATGGTATATTTACGCTAACGTGGGAGATCTGGG
[0102] GCTACGATCCTCTAATAACTTTTTCGTTGCATAAGATCCCGGATCCGCCAC
[0103] AGCCTGACTTTCCGCAGCTCAATTCCGATTGGGTTCCCAGCGTGCGTTCT
[0104] TGGGCGCTCCTACTCAACCAAACAGCAAGAGCGTTCCCCGATTGCGCAAT
[0105] ATGCTGGGAGCCAAGCCCACCCTGGGCACCGGAGATTCTTGTCTATAAT
[0106] AAAACCATTTCCTCATCGGGACCAGGATTGGCATTGCCAGATGCTCAAAT
[0107] ATTCTGGGTCAACACCTCGAGTTTTAACACAACCCAAGGCTGGCACCACC
[0108] CTAGCCAGCGTCTTCTGTTCAATGTCAGTCAAGGGAATGCTCTGTTATTA
[0109] CCGCCAATATCTCTGGTGAACCTATCCACGGCTTCGTCTGCGCCGCCGAC
[0110] CCGGGTTCGTCGGAGTTGAAAGCTTGCTCAACTAGTGCGGCCGCTTTCG
[0111] AATCTAGAGCCTGCAGTCTCGAGGCATGCGGTACCAAGCTTGTCGAGAA
[0112] GTACTAGAGGATCATAATCAGCCATACCACATTTGTAGAGGTTTTACTTG
[0113] CTTTAAAAAACCTCCCACACCTCCCCCTGAACCTGAAACATAAAATGAATG
[0114] CAATTGTTGTTGTTAACTTGTTTATTGCAGCTTATAATGGTTACAAATAAA
[0115] GCAATAGCATCACAAATTTCACAAATAAAGCATTTTTTTCACTGCATTCTA
[0116] GTTGTGGTTTGTCCAAACTCATCAATGTATCTTATCATGTCTGGATCTGA
[0117] TCACTGCTTGAGCCTAGGAGATCCGAACCAGATAAGTGAAATCTAGTTCC
[0118] AAACTATTTTGTCATTTTTAATTTTCGTATTAGCTTACGACGCTACACCCA
[0119] GTTCCCATCTATTTTGTCACTCTTCCCTAAATAATCCTTAAAAACTCCATTT
[0120] CCACCCCTCCCAGTTCCCAACTATTTTGTCCGCCCACAGCGGGGCATTTTT
[0121] CTTCCTGTTATGTTTTTAATCAAACATCCTGCCAACTCCATGTGACAAACC
[0122] GTCATCTTCGGCTACTTTTTCTCTGTCACAGAATGAAAATTTTTCTGTCAT
[0123] CTCTTCGTTATTAATGTTTGTAATTGACTGAATATCAACGCTTATTTGCAG
[0124] CCTGAATGGCGAATGG。
Claims
1. A bovine leukemia virus gp51 eukaryotic recombinant protein, characterized in that: The nucleic acid sequence of the bovine leukemia virus gp51 eukaryotic recombinant protein is shown in SEQ ID NO.1, and the amino acid sequence is shown in SEQ ID NO.
2.
2. A monoclonal antibody against the eukaryotic recombinant protein of bovine leukemia virus gp51, characterized in that: The monoclonal antibody against the bovine leukemia virus gp51 eukaryotic recombinant protein is obtained by immunizing with the bovine leukemia virus gp51 eukaryotic recombinant protein as an antigen.
3. A recombinant plasmid, characterized in that: After the recombinant plasmid is transfected into cells, the recombinant plasmid expresses the bovine leukemia virus gp51 eukaryotic recombinant protein according to claim 1, and the nucleic acid sequence thereof is shown in SEQ ID NO.
3.
4. A receptor cell, characterized in that: The recipient cell is a cell transfected with the recombinant plasmid according to claim 3.
5. The method for preparing a monoclonal antibody against the eukaryotic recombinant protein of bovine leukemia virus gp51 according to claim 2, characterized in that: include: The bovine leukemia virus gp51 sequence was codon-optimized in the insect cell expression system and then constructed into the pFastBac-HTA eukaryotic expression donor plasmid, which was then transposed into DH10Bac competent cells to obtain the corresponding shuttle bacmid. The shuttle bacmid was transfected into Sf9 insect cells to obtain recombinant baculovirus; Lyse Sf9 cells infected with rBv-gp51 to obtain eukaryotically expressed recombinant gp51 protein, and purify the baculovirus-expressed recombinant protein using a Ni column; BALB / c mice were immunized three times with purified recombinant gp51 protein combined with Freund's adjuvant, and the spleen was fused with SP2 / 0 cells and positive hybridoma cells were screened by indirect ELISA.
6. A hybridoma cell strain 3E3 that stably secretes a monoclonal antibody against the eukaryotic recombinant protein of bovine leukemia virus gp51, characterized in that: The hybridoma cell 3E3 has a deposit number of CCTCC NO: C2024192, and reacts with the recombinant gp51 protein expressed by eukaryotes and the gp51 protein in natural conformation / denatured form, and the subtype of the antibody is IgM.
7. Use of the hybridoma cell 3E3 as claimed in claim 6 in detecting bovine leukemia virus gp51 antibodies by competitive ELISA assay.
8. The use according to claim 7, characterized in that: In the competitive ELISA test for detecting bovine leukemia virus gp51 antibodies, the blocking ELISA experiment is carried out using the bovine leukemia virus gp51 eukaryotic recombinant protein as the coating antigen and the hybridoma cell 3E3 culture supernatant as the competitive antibody.
9. The use according to claim 8, characterized in that: The competitive ELISA test for detecting bovine leukemia virus gp51 antibody is as follows: 0.125 μg / mL of recombinant gp51 eukaryotic expression protein is coated in an ELISA plate, 100 μL / well, and coated overnight at 4°C; the plate is washed with PBST; 200 μL of 1% BSA is added to each well for blocking at 37°C for 2 hours; the plate is washed with PBST; 50 μL of a 5-fold diluted serum sample is added and incubated at 37°C for 1 hour; 50 μL of competitive antibody 3E3 hybridoma culture supernatant is added and incubated at 37°C for 1 hour, and the plate is washed with PBST; 50 μL of diluted Goat Anti-Mouse IgM HRP is added to each well and incubated at 37°C for 30 minutes; PBST is washed; 100 μL of TMB colorimetric solution is added and color is developed at room temperature in the dark for 10 minutes; 50 μL of colorimetric stop solution is used to stop color development; and reading is performed using an ELISA reader.
10. The use according to claim 9, characterized in that: After the reading, the S / N value was calculated according to the OD value, and the test result S / N value ≤ 0.4915 was determined as positive; S / N value ≥ 0.6534 was determined as negative, and 0.4915 < S / N value < 0.6534 was determined as suspected.
Citation Information
Patent Citations
Anti-rabbit hemorrhagic disease virus VP60 albumen monoclonal antibody
CN101519447A
Competitive ELISA kit for peste-des-petits-ruminants antibody detection and preparation method thereof
CN102967710A
Recombinant protein of enzootic bovine leukemia virusexpressed in a insect cell and the diagnostic method
KR1020080010771A
Monoclonal Antibodies Specifically Binding to Glycoprotein 51 of Bovine Leukemia Virus and Its Use
KR1020160104785A
